3.925
price down icon3.09%   -0.125
 
loading
Precedente Chiudi:
$4.05
Aprire:
$4.03
Volume 24 ore:
719.03K
Relative Volume:
0.73
Capitalizzazione di mercato:
$285.89M
Reddito:
$20.76M
Utile/perdita netta:
$-132.49M
Rapporto P/E:
-1.3772
EPS:
-2.85
Flusso di cassa netto:
$-108.55M
1 W Prestazione:
-16.84%
1M Prestazione:
-37.20%
6M Prestazione:
-31.86%
1 anno Prestazione:
+165.20%
Intervallo 1D:
Value
$3.89
$4.12
Intervallo di 1 settimana:
Value
$3.84
$4.9298
Portata 52W:
Value
$1.06
$11.88

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name
Nome
C 4 Therapeutics Inc
Name
Telefono
(617) 231-0700
Name
Indirizzo
490 ARSENAL WAY, WATERTOWN
Name
Dipendente
145
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
CCCC's Discussions on Twitter

Confronta CCCC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
CCCC 3.925 285.89M 20.76M -132.49M -108.55M -2.85
VRTX 449.99 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.40 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 593.04 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.04 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.32 24.89B 3.30B -501.07M 1.03B 11.54

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-02-24 Aggiornamento Credit Suisse Underperform → Neutral
2023-02-24 Downgrade JP Morgan Neutral → Underweight
2022-11-04 Downgrade JP Morgan Overweight → Neutral
2022-10-11 Iniziato Morgan Stanley Underweight
2022-04-28 Iniziato Credit Suisse Underperform
2022-04-11 Downgrade BofA Securities Buy → Neutral
2022-03-10 Iniziato JP Morgan Overweight
2022-02-11 Ripresa BMO Capital Markets Outperform
2022-02-10 Iniziato Wells Fargo Equal Weight
2021-11-23 Iniziato BofA Securities Buy
2021-10-14 Iniziato SVB Leerink Mkt Perform
2021-09-30 Iniziato Stifel Hold
2021-06-04 Iniziato H.C. Wainwright Buy
2021-03-31 Iniziato BMO Capital Markets Outperform
2020-10-28 Iniziato UBS Buy
2020-10-27 Iniziato BMO Capital Markets Outperform
2020-10-27 Iniziato Jefferies Buy
Mostra tutto

C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie

pulisher
Nov 20, 2024

C4 Therapeutics appoints Steve Hoerter to board - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics appoints Steve Hoerter to board By Investing.com - Investing.com UK

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - The Bakersfield Californian

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics Adds Oncology Veteran Steve Hoerter to Board, Brings Drug Launch Expertise | CCCC Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors - Marketscreener.com

Nov 20, 2024
pulisher
Nov 19, 2024

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Nov 19, 2024
pulisher
Nov 18, 2024

Stephens Initiates Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Stephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight Recommendation - MSN

Nov 18, 2024
pulisher
Nov 16, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 15, 2024
pulisher
Nov 15, 2024

Orbimed Advisors LLC Increases Stake in C4 Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St

Nov 15, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024
pulisher
Nov 11, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 11, 2024
pulisher
Nov 08, 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 08, 2024
pulisher
Nov 08, 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Nov 08, 2024
pulisher
Nov 06, 2024

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

CCCCC4 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

C4 Therapeutics Launches Phase 1 Trial in China: $357M Cancer Drug Partnership Advances | CCCC Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 05, 2024
pulisher
Nov 05, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

C4 Therapeutics' Cemsidomide Trial Data Selected for Key ASH Presentations in NHL, Myeloma | CCCC Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 05, 2024
pulisher
Nov 04, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 04, 2024
pulisher
Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Will C4 Therapeutics' Upcoming Multiple Myeloma And NHL Trial Results Drive Stock Recovery? - RTTNews

Nov 04, 2024
pulisher
Nov 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Nov 01, 2024
pulisher
Nov 01, 2024

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics (CCCC) Q3 2024 Earnings: Revenue Surges to $15.4M, GAAP EPS Loss Narrows to $0.35 - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 31, 2024
pulisher
Oct 29, 2024

We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 29, 2024
pulisher
Oct 26, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune

Oct 25, 2024
pulisher
Oct 17, 2024

C4 Therapeutics appoints Paige Mahaney as new CSO - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 16, 2024

C 4 Therapeutics Inc Azioni (CCCC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):